Oxygen Biotherapeutics to Host 2013 Annual Meeting of Shareholders Business Wire MORRISVILLE, N.C. -- December 3, 2013 Oxygen Biotherapeutics, Inc., (NASDAQ: OXBT) a developer of oxygen-carrying therapeutics, today announced it will webcast its 2013 Annual Meeting of Shareholders on Wednesday, December 4, 2013 beginning at 9:00am ET at the offices of Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan, L.L.P. located at Wells Fargo Capitol Center, 150 Fayettville Street, Suite 2300, Raleigh, NC 27601. Oxygen Biotherapeutics’ CEO John Kelley and CFO Michael Jebsen will be hosting the call. A listen only teleconference will be available in real-time by dialing (877) 836-0197. To listen to the live webcast, please access the link https://event.webcasts.com/starthere.jsp?ei=1026689, at least 15 minutes prior to register. A replay of the call will be made available until June 4, 2014. About Phyxius Pharma Phyxius Pharma, Inc. is a privately-held development stage pharmaceutical company. The company is focused on developing products for use in acute care settings. The company has licensed North American rights to develop and commercialize levosimendan from Orion Pharma, Orion Corporation of Espoo, Finland. About Oxygen Biotherapeutics, Inc. Oxygen Biotherapeutics, Inc. is developing medical products that efficiently deliver oxygen to tissues in the body. The company has developed a proprietary perfluorocarbon (PFC) therapeutic oxygen carrier called Oxycyte^® that is currently in clinical and preclinical studies for intravenous delivery for indications such as traumatic brain injury, decompression sickness and stroke. Caution Regarding Forward-Looking Statements This news release contains certain forward-looking statements by the Company that involve risks and uncertainties and reflect the company’s judgment as of the date of this release. The forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, delays in new product introductions and customer acceptance of these new products, and other risks and uncertainties as described in our filings with the Securities and Exchange Commission, including in the current Form 10-Q filed on September 17, 2013, and our annual report on Form 10-K filed on June 26, 2013, as well as other filings with the SEC. The company disclaims any intent or obligation to update these forward-looking statements beyond the date of this release. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Contact: IRTH Communications Robert Haag, 1-866-976-4784 email@example.com
Oxygen Biotherapeutics to Host 2013 Annual Meeting of Shareholders
Press spacebar to pause and continue. Press esc to stop.